CHICAGO — A transcatheter aortic valve implantation (TAVI) device developed specifically for the treatment for aortic regurgitation has met all the prespecified safety and efficacy goals, so far, in ...

ATLANTA, GA—Once again TAVI has proved noninferior to surgical aortic valve replacement for patients at low or intermediate risk with regard to all-cause death or stroke at 1 year, according to new ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--According to a new series of reports by iData Research, the European cardiac surgery device market is valued at $2.7 billion USD, and is expected to grow ...

Abbott is now entering a corner of the medical device space that has been dominated by Edwards Lifesciences and Medtronic. On Tuesday, the company earned FDA approval for its latest transcatheter ...

Around one in every nine patients who undergo TAVI with a new-generation self-expanding device will need permanent pacemaker implantation (PPI) within the next 30 days, according to an analysis of ...

The CE Mark pivotal study is ongoing, and 120 patients are planned to be enrolled. In Barcelona, Treede reported on the first 61 patients to receive the valve, although one did not receive the Engager ...

Abbott said it is building the foundation for artificial intelligence-guided procedures with its new transcatheter aortic valve implantation (TAVI) balloon-expandable system. This effort could help ...

“This 3rd-generation TRINITY technology could be a game-changer for TAVI.” Prof. Dr. Christian Hengstenberg, MD, German Heart Center, Munich (Note: Prof. Dr. med Hengstenberg has no financial ties to ...

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were ...